Patents by Inventor Levi A. Garraway

Levi A. Garraway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11186874
    Abstract: Isolated mutant ERK polypeptides and nucleic acids encoding the mutant ERK polypeptides are provided. Methods of screening cancer-containing samples for an ERK polypeptide mutation that confers resistance to treatment with a first MAPK pathway inhibitor are provided. Methods of optimizing treatment of a subject having cancer and methods of identifying compounds useful in treating cancer are also provided.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: November 30, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Eva M. Goetz, Levi A. Garraway
  • Publication number: 20210277482
    Abstract: The invention provides methods and devices for determining molecular signatures in a cancer that predict response to a MARPK pathway inhibitor and methods of use of such signatures.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 9, 2021
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Cory M. Johannessen, David J. Konieczkowski, Levi A. Garraway
  • Patent number: 11078540
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: August 3, 2021
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., BROAD INSTITUTE, INC.
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Patent number: 10968484
    Abstract: The invention provides methods and devices for determining molecular signatures in a cancer that predict response to a MARPK pathway inhibitor and methods of use of such signatures.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 6, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Cory M. Johannessen, David J. Konieczkowski, Levi A. Garraway
  • Publication number: 20210008147
    Abstract: Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
    Type: Application
    Filed: August 25, 2020
    Publication date: January 14, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Caroline Emery, Nikhil Wagle
  • Publication number: 20200390786
    Abstract: Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in patients with ovarian cancer.
    Type: Application
    Filed: March 30, 2018
    Publication date: December 17, 2020
    Inventors: Levi Garraway, Benjamin Izar, Aviv Regev, Orit Rozenblatt-Rosen, Asaf Rotem, Elizabeth Stover, Itay Tirosh
  • Patent number: 10788496
    Abstract: Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: September 29, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Levi A. Garraway, Caroline Emery, Nikhil Wagle
  • Publication number: 20200157563
    Abstract: The present invention provides methods for introducing mutations to primary cells and selecting for the mutations to obtain a population of cells for modeling cancer. Such methods may comprise at least one round of introducing one or more mutations into one or more cells in a population of cells in vitro and culturing the cells until the mutation(s) are positively selected in the population. The cells may be cultured in vitro. The cells may be cultured in vivo. In certain embodiments, the cells are positively selected in vivo in order to select for cells capable of evading the immune system. In certain embodiments, cells are selected in an immune competent animal model. The cells may primary cells. The population of cells may be used for drug screening and for studying cancer.
    Type: Application
    Filed: July 18, 2018
    Publication date: May 21, 2020
    Inventors: Eran Hodis, Levi Garraway, Aviv Regev
  • Publication number: 20190367964
    Abstract: Described herein are compositions and methods of disaggregating a tissue sample into single cells.
    Type: Application
    Filed: February 2, 2017
    Publication date: December 5, 2019
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Benjamin Izar, Levi Garraway, Asaf Rotem, Aviv Regev, Alexander Shalek, Marc Wadsworth, Sanjay Prakadan, Orit Rozenblatt-Rosen, Itay Tirosh
  • Publication number: 20190142830
    Abstract: Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.
    Type: Application
    Filed: January 23, 2019
    Publication date: May 16, 2019
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Caroline Emery, Rajee Antony, Levi A. Garraway
  • Publication number: 20180271891
    Abstract: The present invention generally relates to therapeutic inhibition of protein arginine methyltransferase 5 (PRMT5). In particular, cell lines having MTAP loss and increased intracellular MTA concentrations show selective dependence on PRMT5. Thus, the invention also relates to methods of identifying and treating PRMT5-related diseases in subjects or tissues which have an MTAP deficiency, alone or in combination, with a second agent that reduces MTAP activity and/or increases intracellular MTA levels, and/or provides an MTA analogs to the cell or tissue. The invention also relates to the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas System and components thereof. More specifically, the present invention relates to the delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions in tumor cells ex vivo and/or in vivo. For example using methods disclosed herein, cells can be sensitized to PRMT5 inhibition.
    Type: Application
    Filed: March 10, 2016
    Publication date: September 27, 2018
    Inventors: Levi A. Garraway, Grigoriy Kryukov, Jason Ruth, Frederick Wilson
  • Publication number: 20180217147
    Abstract: Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
    Type: Application
    Filed: December 15, 2017
    Publication date: August 2, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Caroline Emery, Nikhil Wagle
  • Publication number: 20180100201
    Abstract: This invention relates generally to compositions and methods for identifying genes and gene networks that respond to, modulate, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells, and provides compositions and methods of modulating expression of genes and gene networks of tumors, tissues and cells, as well as methods of identifying, designing and selecting appropriate treatment regimens. The invention also relates to the modulation of complement activity to shift cellular immunity and obtain an effective therapeutic response.
    Type: Application
    Filed: December 17, 2017
    Publication date: April 12, 2018
    Inventors: Levi A. Garraway, Benjamin Izar, Sanjay Prakadan, Aviv Regev, Orit Rozenblatt-Rosen, Alexander K. Shalek, Mario Suva, Itay Tirosh, Andrew Venteicher, Marc H. Wadsworth II, Bradley Bernstein, Anuraag Parikh, Sidharth Puram
  • Publication number: 20180066322
    Abstract: The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Cyclin Dependent kinase inhibitors (CDKi), methods of determining the sensitivity of a cell to a CDKi, methods of treating a patient with a CDKi and methods of screening for candidate CDKi.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 8, 2018
    Inventors: Giordano Caponigro, Scott Delach, Levi Garraway, Zainab Jagani, Sunkyu Kim, Gregory Kryukov
  • Patent number: 9880169
    Abstract: Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: January 30, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Caroline Emery, Nikhil Wagle
  • Publication number: 20170268065
    Abstract: Isolated mutant ERK polypeptides and nucleic acids encoding the mutant ERK polypeptides are provided. Methods of screening cancer-containing samples for an ERK polypeptide mutation that confers resistance to treatment with a first MAPK pathway inhibitor are provided. Methods of optimizing treatment of a subject having cancer and methods of identifying compounds useful in treating cancer are also provided.
    Type: Application
    Filed: June 11, 2015
    Publication date: September 21, 2017
    Inventors: Eva M. Goetz, Levi A. Garraway
  • Publication number: 20170268069
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.
    Type: Application
    Filed: April 5, 2017
    Publication date: September 21, 2017
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Publication number: 20170204383
    Abstract: Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 20, 2017
    Inventors: Caroline Emery, Rajee Antony, Levi A. Garraway
  • Patent number: 9629839
    Abstract: Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: April 25, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Caroline Emery, Rajee Antony, Levi A. Garraway
  • Publication number: 20160299146
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.
    Type: Application
    Filed: November 20, 2014
    Publication date: October 13, 2016
    Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Levi Garraway, Marios Giannakis, Grigoriy V. Kryukov